Search results for "lung function"

showing 10 items of 106 documents

An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly.

2016

Asthma in the elderly (>65 yr old) is common and associated with higher morbidity and mortality than asthma in younger patients. The poor outcomes in this group are due, in part, to underdiagnosis and undertreatment. There are a variety of factors related to aging itself that affect the presentation of asthma in the elderly and influence diagnosis and management. Structural changes in the aging lung superimposed on structural changes due to asthma itself can worsen the disease and physiologic function. Changes in the aging immune system influence the cellular composition and function in asthmatic airways. These processes and differences from younger individuals with asthma are not well u…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAgingImmunosenescenceaging; immunosenescence; lung function; phenotype; reactive airways diseaseDiseaseComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Diagnosis Differential03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineimmune system diseasesreactive airways diseasemedicineHumans030212 general & internal medicineDisease management (health)LungSocieties MedicalAsthmaAgedAmerican Thoracic Society DocumentsLungbusiness.industryDisease Managementlung functionImmunosenescencemedicine.diseaseComorbidityAsthmaUnited Statesrespiratory tract diseasesmedicine.anatomical_structurePhenotype030228 respiratory systemPhysical therapyAge of onsetbusinessBiomarkersAnnals of the American Thoracic Society
researchProduct

CAT score single item analysis in patients with COPD: results from COSYCONET

2019

Abstract The COPD Assessment Test (CAT) is in widespread use for the evaluation of patients with chronic obstructive pulmonary disease (COPD). We assessed whether the CAT items carry additional information beyond the sum score regarding COPD characteristics including emphysema. Patients of GOLD grades 1 to 4 from the COPD cohort COSYCONET (German COPD and Systemic Consequences - Comorbidities Network) with complete CAT data were included (n = 2270), of whom 493 had chest CT evaluated for the presence of emphysema. Comorbidities and lung function were assessed following standardised procedures. Cross-sectional data analysis was based on multiple regression analysis of the single CAT items ag…

Pulmonary and Respiratory MedicinePercentilemedicine.medical_specialtyMedizinDiagnostic Techniques Respiratory System610Single itemCAT score03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicineCOPDIn patient030212 general & internal medicineLung functionEmphysemaCOPDbusiness.industryRegression analysisCat Score ; Copd ; Emphysemamedicine.diseaseExploratory factor analysisrespiratory tract diseases030228 respiratory systemCohortbusiness61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
researchProduct

P120 Real life distribution of COPD severity in the German DACCORD registry: Lung function is the main driver of classification in GOLD group C and D

2015

Introduction Currently there is limited real-life data available regarding the distribution of COPD patients using the GOLD 2011 criteria. The German DACCORD registry that collects data from a large ‘real life’ population sample was used to categorise COPD patients according to GOLD 2011. Methods To be eligible for entry into DACCORD, all patients had to have a diagnosis of COPD (consistent with the German Disease Management Programme definition), and, prior to entry, had to have either newly initiated bronchodilator maintenance medication, or to have a bronchodilator added to their maintenance regimen. No other inclusion criteria were applied, and the only exclusion criterion was a diagnos…

Pulmonary and Respiratory MedicineSpirometryPediatricsmedicine.medical_specialtyCOPDExacerbationmedicine.diagnostic_testbusiness.industrymedicine.drug_classDiseasemedicine.diseaseRegimenBronchodilatormedicinebusinessLung functionAsthmaThorax
researchProduct

Validation of FEV6 in the elderly: correlates of performance and repeatability.

2007

BACKGROUND: Forced expiratory volume in 6 s (FEV6) has been proposed as a more easily measurable parameter than forced vital capacity (FVC) to diagnose airway disease using spirometry. A study was undertaken to estimate FEV6 repeatability, to identify correlates of a good quality FEV6 measurement and of volumetric differences between FEV6 and FVC in elderly patients. METHODS: 1531 subjects aged 65-100 years enrolled in the SA.R.A project (a cross-sectional multicentre non-interventional study) were examined. FEV6 was measured on volume-time curves that achieved satisfactory start-of-test and end-of-test criteria. Correlates of FEV6 achievement were assessed by logistic regression. RESULTS: …

Pulmonary and Respiratory MedicineSpirometryVital capacitymedicine.medical_specialtyCross-sectional studyPopulationVital CapacitySettore MED/10 - Malattie Dell'Apparato RespiratorioLogistic regressionFEV1/FVC ratioForced Expiratory VolumemedicineHumanseducationAgedAged 80 and overeducation.field_of_studymedicine.diagnostic_testbusiness.industryReproducibility of ResultsBronchial DiseasesRepeatabilityrespiratory systemAirway obstructionlung function agingmedicine.diseaserespiratory tract diseasesCross-Sectional StudiesPhysical therapybusiness
researchProduct

Early childhood growth is associated with lung function at 7 years: a prospective population-based study

2020

Previous studies have related early postnatal growth with later lung function but their interpretation is limited by the methods used to assess a child's growth. We aimed to assess the association of early childhood growth, measured by body mass index (BMI) trajectories up to 4 years, with lung function at 7 years.We included 1257 children from the Spanish Infancia y Medio Ambiente population-based birth cohort. Early childhood growth was classified into five categories based on BMI trajectories up to 4 years previously identified using latent class growth analysis. These trajectories differed in birth size ("lower", "average", "higher") and in BMI gain velocity ("slower", "accelerated"). W…

Pulmonary and Respiratory MedicineVital capacityVital CapacityPopulation03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineForced Expiratory VolumeHumansMedicineProspective Studies030212 general & internal medicineEarly childhoodPostnatal growthChildeducationLungLung function2. Zero hungereducation.field_of_studybusiness.industryrespiratory systemRespiratory Function TestsPopulation based study030228 respiratory systemChild PreschoolPulmonsbusinessBody mass indexDemographyInfància
researchProduct

Bronchial responsiveness and airway inflammation in trained subjects

2008

We read with interest the paper by Shaaban and coworkers1 on the protective effect of physical activity against bronchial hyperreactivity (BHR) in the general population. The authors suggest that a beneficial effect of deep inspirations during exercise could account for the lower prevalence of BHR in physically active subjects compared with sedentary subjects, while the accompanying editorial2 favours an “anti-inflammatory” effect of exercise as the most plausible explanation. We have studied lung function and airway cell biology …

Pulmonary and Respiratory Medicineeducation.field_of_studybusiness.industryPopulationAirway inflammationPhysical activityrespiratory systemImmunologyLower prevalenceMedicinebusinessAirwayeducationTrained subjectsLung functionBronchial hyperreactivityThorax
researchProduct

Alternative mechanisms for tiotropium

2009

Tiotropium is commonly used in the treatment of chronic obstructive pulmonary disease. Although largely considered to be a long-acting bronchodilator, its demonstrated efficacy in reducing the frequency of exacerbations and preliminary evidence from early studies indicating that it might slow the rate of decline in lung function suggested mechanisms of action in addition to simple bronchodilation. This hypothesis was examined in the recently published UPLIFT study and, although spirometric and other clinical benefits of tiotropium treatment extended to four years, the rate of decline in lung function did not appear to be reduced by the addition of tiotropium in this study. This article summ…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyANTICHOLINERGIC BRONCHODILATORmedicine.drug_classRespiratory SystemScopolamine DerivativesPulmonary diseaseIPRATROPIUM BROMIDEIpratropium bromideOBSTRUCTIVE PULMONARY-DISEASEMUCOCILIARY CLEARANCECholinergic AntagonistsRECEPTORS MEDIATE STIMULATIONParasympathetic Nervous SystemAIRWAY SMOOTH-MUSCLEBronchodilatorBronchodilationMechanismsBRONCHIAL EPITHELIAL-CELLSAnimalsHumansMedicineCOPDPharmacology (medical)Tiotropium BromideIntensive care medicineLungLung functionInflammationCOPDbusiness.industryTiotropiumBiochemistry (medical)RemodellingTiotropium bromidemedicine.diseaseAcetylcholineBronchodilator Agentsrespiratory tract diseasesMucusClinical researchNONNEURONAL CHOLINERGIC SYSTEMCoughPOLYSPECIFIC CATION TRANSPORTERSAnesthesiaLUNG FIBROBLAST PROLIFERATIONbusinesshuman activitiesmedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy

2017

Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies. This secondary analysis assessed reslizumab's efficacy in patients receiving baseline treatment per Global Initiative for Asthma (GINA) Step 4 and Step 5 guidelines. Pooled data from duplicate, Phase III, reslizumab versus placebo studies in patients with severe eosinophilic asthma (blood eosinophils ≥400 cells·µL−1) were stratified by baseline therapy. Efficacy assessments were exacerbation rates and changes from baseline forced expiratory volume in …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbation2lcsh:MedicineEosinophilic asthmaPlacebo03 medical and health sciences0302 clinical medicineQuality of lifeReslizumabInternal medicineSecondary analysismedicineMedicine and Health Sciences030212 general & internal medicineLung functionAsthmabusiness.industrylcsh:ROriginal Articlesmedicine.diseaseSurgery030228 respiratory systembusinessmedicine.drugERJ Open Research
researchProduct

Impact of long-term treatment with inhaled corticosteroids and bronchodilators on lung function in a patient with post-infectious bronchiolitis oblit…

2016

Post-infectious bronchiolitis obliterans (PIBO) is a small airways disease characterized by fixed airflow limitation. Therefore, inhaled bronchodilators and corticosteroids are not recommended as maintenance therapy options. The management of PIBO currently consists only of close monitoring of affected patients, aimed at the prevention and early treatment of pulmonary infections. In recent years, there has been an increase in the incidence of PIBO in the pediatric population. Patients with PIBO are characterized by a progressive decline in lung function, accompanied by a decrease in overall functional capacity. Here, we report the case of a relatively young man diagnosed with PIBO and follo…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyLong term treatmentmedicine.drug_classmedicine.medical_treatmentBronchiolitis obliteransInhaled corticosteroidsAnti-inflammatory agents/ therapeutic useCase ReportMuscarinic antagonists/therapeutic use03 medical and health sciences0302 clinical medicineAnti-inflammatory agents/therapeutic useBronchodilatormedicinePulmonary rehabilitation030212 general & internal medicineBronchiolitis obliterans/therapyLung functionGynecologylcsh:RC705-779Administration inhalationinhalationbusiness.industrylcsh:Diseases of the respiratory systemmedicine.diseaseAdministration inhalation; Adrenergic beta-2 receptor antagonists/therapeutic use; Anti-inflammatory agents/ therapeutic use; Bronchiolitis obliterans/therapy; Infection/complications; Lung diseases/rehabilitation; Muscarinic antagonists/therapeutic use; Pulmonary and Respiratory MedicineLung diseases/rehabilitation030228 respiratory systemPhysical performanceInfection/complicationAnesthesiaInfection/complicationsAdministrationbusinessAdrenergic beta-2 receptor antagonists/therapeutic usePediatric populationJornal Brasileiro de Pneumologia
researchProduct

Lung Function Monitoring; A Randomized Agreement Study

2016

Objective: To determine the agreement between devices and repeatability within devices of the forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory flow at 50% of FVC (FEF50) values measured using the four spirometers included in the study. Methods: 50 (24 women) participants (20-64 years of age) completed maximum forced expiratory flow manoeuvres and measurements were performed using the following devices: MasterScreen, SensorMedics, Oxycon Pro and SpiroUSB. The order of the instruments tested was randomized and blinded for both the participants and the technicians. Re-testing was conducted on a following day within 72 hours …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyVital capacitySpirometersTestingArticleMean difference03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineInternal medicinemedicineAdultsRepeatability030212 general & internal medicineLung functionReproducibilitybusiness.industryMeasurementsRepeatabilityrespiratory systemReproducibilityConfidence intervalrespiratory tract diseases030228 respiratory systemPhysical therapyCardiologybusinessThe Open Respiratory Medicine Journal
researchProduct